Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

ABSTRACT:

Aims

Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin-angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia. We evaluated the effects of finerenone according to anaemia status in patients with HFmrEF/HFpEF enrolled in FINEARTS-HF. Additionally, we examined the effect of finerenone on haemoglobin, new-onset anaemia, and resolution of anaemia during follow-up.

Methods and results

Anaemia was defined as haemoglobin <12 g/dl in women and <13 g/dl in men. The primary outcome was the composite of total (first and recurrent) heart failure events and cardiovascular

SUBMITTER: Chimura M 

PROVIDER: S-EPMC12765042 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature